OTC Monograph Legislation Clears Another Hurdle Despite Exclusivity Concerns
This article was originally published in The Rose Sheet
Executive Summary
Democrats' opposition to the length of the exclusivity allowed for some new monograph products didn't stop them from voting to send US OTC monograph overhaul legislation on for a vote by the full House. House/Senate differences and some members' questions on whether new exclusivity is needed could make it harder for reforms to pass this year.
You may also be interested in...
Unilever Divests Dollar Shave Club, Focused On 30 ‘Power Brands’ Under New CEO’s Action Plan
More brands, particularly those acquired prior to Unilever’s 2019 shift in M&A strategy, could be on the chopping block, according to CEO Hein Schumacher, who took the helm in July. His targeted action plan includes investments to accelerate innovation and increase brand and marketing support.
Monograph Reform Legislation In Play As FDA, OTC Industry Get Real On Changes
FDA and CHPA preparing for changes to monograph procedures the agency and industry negotiated, including a user fee program, and are included in legislation passed by House and introduced in Senate. But neither the agency nor the trade group expects to be entirely ready before the legislation passes, whenever that might be.
OTC Monograph Reform Passes House Again As Clock Ticks On Session
House Energy and Commerce Democrat and Republican members who back monograph reform are co-sponsors of Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018, which also includes provisions largely tracking with standalone monograph reform legislation that passed the House in July, including allowing 18-month market exclusivity periods for some ingredients, formulations or indications added to a monograph.